ArticleMolecular cancer therapeutics2020

First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.

Joshua M Abbott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.